The FDA is expected to issue a new warning on the J&J COVID jab | Business and Financial Issues

The US FDA is expected to issue a new warning for Johnson & Johnson’s COVID-19 vaccine, linking it to an allergy, The Washington Post reported Monday.

The United States Food and Drug Administration (FDA) plans to issue a new warning for Johnson & Johnson’s COVID-19 vaccine, linking it to an autoimmune disease, The Washington Post reported Monday, citing four people familiar with the matter.

The U.S. Centers for Disease Control and Prevention (CDC) reports Monday that the first 100 reports of Guillain-Barre syndrome – an autoimmune disease – have been found after 12.8 million J & J’s COVID- 19 jab map in the US.

Most common infections are reported in people 50 years of age or older, usually two weeks after vaccination.

About 3,000 to 6,000 people in the US have Guillain-Barre infections each year. The disease, which is not uncommon, is often caused by viruses or bacteria.

Guillain-Barre’s epidemic was linked to the swine flu vaccine in 1970, the Washington Post reported.

A new warning could be the recent problem of J & J’s COVID vaccine – which requires only one jab and can be stored more easily than the two-group mRNA vaccine developed by Moderna and Pfizer / BioNTech.

In April, the CDC and the FDA sought to suspend the use of the J&J vaccine for COVID-19 after being linked to serious blood cases, but raised the issue for a while after realizing that the vaccine outweighed its risks.

J & CO’s COVID-19 jab also suffered from early preparations this year which resulted in 75 levels of vaccine being thrown away.

European authorities have reiterated a similar warning that the AstraZeneca vaccine for COVID-19 could pose an increased risk of Guillain-Barre disease.